Agenda
National
Cancer Policy Forum Workshop onExtending the Spectrum of
Precompetitive Oncology Biomedical Research
The Keck Center
of The National Academies
500 Fifth Street, NW - Room 100
Washington, D.C. 20001
Day 1 -
Tuesday, February 9, 2010
8:00 am - Registration and
Continental Breakfast
8:30 am - Welcome from NCPF/IOM and
Overview of the Workshop
Hal Moses, MD, National Cancer Policy Forum Chair
John
Wagner, MD, PhD, Merck & Co., Inc.
8:45 am - General characterization
of the precompetitive collaboration environment
Session
chair: John Wagner, MD, PhD, Merck & Co., Inc.
Open innovation networks between
academia and industry
Neal Cohen,
MD, MPH, MS, University of California
San Francisco School
of Medicine
Overview of precompetitive
collaboration with exemplar models
Jill
Altshuler, MBA, AltshulerGray
Open access integrative bionetworks
Stephen
Friend, MD, PhD, Sage Bionetworks
PatientsLikeMe
James
Heywood
Panel discussion 30 minutes
11:15 am - Break
11:30 am - Precompetitive
collaboration in science
Session
chair: Roy Herbst, MD, PhD, M.D.
Anderson Cancer
Center
SEMATECH
William
Spencer, PhD
Science Commons
Thinh
Nguyen, JD
Panel discussion 20 minutes
12:30 pm - Lunch
1:30 pm - Precompetitive
collaboration in biomedicine
Session
chair: Stephen Friend, MD, PhD, Sage Bionetworks
The Biomarkers Consortium
David
Wholley, M. Phil., Foundation for the National Institutes of Health
Critical Path Institute
Ray
Woosley, MD, PhD
Breakthrough innovation
Bernard
Munos, MBA, PhD, Eli Lilly & Co.
Precompetitive informatics
initiatives in drug discovery
Bryn
Williams-Jones, Pfizer
Discussion 30 minutes
3:45 pm - Break
4:00 pm - Day 1 concluding thoughts
Open source science
Karim R.
Lakhani, PhD, MS, Harvard
Business School
Discussion 30 minutes
5:00 pm - Adjourn Day 1
6:00 pm - Speakers, Forum members,
Planning committee dinner with continued discussion
Day 2 - Wednesday,
February 10, 2010
8:00 am - Registration and
Continental Breakfast
8:30 am - Thoughts on Day 1 and
report back from dinner discussion
8:45 am - Precompetitive collaboration
in oncology
Session
chair: Pending
ISPY2 trial
Laura
Esserman, MD, MBA, UCSF
Carol Franc
Buck Breast
Care Center
The Cancer Genome Atlas
Joe
Vockley, PhD, National Cancer Institute
Merck, AstraZeneca drug combination
Pearl
Huang, PhD, Merck & Co., Inc.
CEO Roundtable on Cancer’s Life
Sciences Consortium
Gregory
Curt, MD, AstraZeneca
Imaging studies
Gary
Kelloff, MD, National Cancer Institute
Panel discussion 30 minutes
11:30 am - Break—pick up boxed
lunches and return for final session
11:45 am - Lessons learned and
future directions for precompetitive collaboration in oncology
Session
chair: John Wagner, MD, PhD, Merck & Co., Inc.
Opening Remarks
Mark McClellan, MD, PhD, Brookings Institution’s Engelberg Center
for Health Care Reform
Panelists:
Jill
Altshuler, MBA, AltshulerGray
Neal Cohen,
MD, MPH, MS, University of California
San Francisco School
of Medicine
Stephen
Eck, MD, PhD, Eli Lilly & Co.
Mark
McClellan, MD, PhD, Brookings Institution’s Engelberg Center
for Health Care Reform
Ray
Woosley, MD, PhD, Critical Path Institute
1:30 pm - Adjourn Day 2
Back to Meeting